A Mab A Case Study In Bioprocess Development |top| <2027>

The A-Mab study systematically walks through this risk assessment for a range of quality attributes, including aggregation, glycosylation, deamidation, oxidation, and residual process-related impurities like host cell proteins (HCPs) and leached Protein A. For each attribute, the case study demonstrates the use of risk assessment tools to determine its criticality. For example, while a certain level of aggregation might significantly impact patient safety and is thus a CQA, the exact distribution of C-terminal lysine truncation variants might have a lower risk profile if clinical data shows it doesn't affect efficacy.

The case study explores optimization across the entire manufacturing lifecycle: A–Mab: A Case Study in Bioprocess Development - ISPE

The initial Protein A step used MabSelect SuRe™ resin. Loading at 30 g A Mab/L resin captured >99% of product, but elution at pH 3.5 caused significant aggregation (from 1.5% to 7%).

: Minimizing acidic and basic variants caused by deamidation or C-terminal lysine clipping. A Mab A Case Study In Bioprocess Development

Implementation of QbD strategies in the inoculum expansion ... - PMC

For mAb-X, high-concentration formulation was required for subcutaneous injection (a shot under the skin) rather than an intravenous (IV) drip. This meant packing a lot of protein into a small volume (100 mg/mL).

| Parameter | Initial | Final Process | | :--- | :--- | :--- | | Viable Cell Density | 15e6 cells/mL | 38e6 cells/mL | | Titer | 3.2 g/L | | | Aggregates (Harvest) | 15.2% | 5.8% | | HCP (Harvest) | 850 ppm | 320 ppm | The A-Mab study systematically walks through this risk

Once a high-performing clone is selected, the focus shifts to optimizing the bioreactor environment to support maximum cell growth and antibody production. Companies often leverage platform media and feed systems designed for versatility, performance, and scalability. These solutions support higher cell densities and titers, simplifying the transition from small-scale development to pilot and commercial manufacturing.

In 2009, the CMC Biotech Working Group, a consortium of leading biopharmaceutical companies including Genentech, Amgen, and GSK, published . This landmark document was created to serve as a detailed, practical example of how to apply the International Council for Harmonisation (ICH) guidelines Q8(R2), Q9, and Q10—which cover pharmaceutical development, quality risk management, and pharmaceutical quality systems—to a biotechnology-derived product.

The monoclonal antibody (mAb) in this case study, denoted as mAb-A, targets a specific antigen involved in the progression of a certain type of cancer. The antibody was generated through a combination of immunization, hybridoma technology, and clone selection. With promising preclinical results, the next step was to develop a scalable bioprocess for its production. The case study explores optimization across the entire

The process remained stable even with minor variations in raw materials. Key Takeaway:

Monoclonal antibodies (mAbs) represent the largest sector of the modern biopharmaceutical industry. However, translating a therapeutic candidate from the laboratory bench to commercial-scale manufacturing is a complex engineering feat.

: Purification steps (chromatography and filtration) are optimized to remove impurities like variants and viruses.

The process begins by defining the , which outlines the desired clinical safety and efficacy of the antibody. From this, scientists identify Critical Quality Attributes (CQAs) —physical, chemical, or biological properties that must be within an appropriate limit to ensure product quality.

The A Mab heavy and light chain genes were cloned into a single vector under a strong CMV promoter. After transfection, 5,000 clones were screened using (for specific productivity) and ClonePix (for secretion rate). Clone A-Mab-7B12 was selected based on: